2019
DOI: 10.1007/s10753-019-01098-8
|View full text |Cite
|
Sign up to set email alerts
|

Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
50
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 106 publications
(53 citation statements)
references
References 38 publications
0
50
0
Order By: Relevance
“…Moreover, activation of the NLRP3 inflammasome was also affected by ERS inhibition. MCC950 is a specific small molecule that selectively inhibits the NLRP3/ASC/Caspase1 signalling cascade [65]. At present, its therapeutic effects have been widely revealed in preclinical models of inflammation-associated diseases.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, activation of the NLRP3 inflammasome was also affected by ERS inhibition. MCC950 is a specific small molecule that selectively inhibits the NLRP3/ASC/Caspase1 signalling cascade [65]. At present, its therapeutic effects have been widely revealed in preclinical models of inflammation-associated diseases.…”
Section: Discussionmentioning
confidence: 99%
“…Some promising selective inhibitors and medicines already used to treat other diseases are found to target various aspects of inflammasome activation regulated by NEK7. These inhibitors may disrupt the upstream events or directly regulate the expression or modification of NEK7 and NLRP3 thus effecting their interaction (Zhang Y. et al, 2017;He et al, 2018;Chiu et al, 2019;Wu et al, 2019;Liu D. et al, 2020;Shi et al, 2020).…”
Section: Inhibitors and Their Application To Diseasesmentioning
confidence: 99%
“…Among these inhibitors, MCC950 is the best characterized for its potent effect in many diseases with NEK7-NLRP3mediated inflammasome activation (Wu et al, 2019), including high glucose-induced human retinal endothelial cell dysfunction (diabetic retinopathy) (Zhang Y. et al, 2017), lung ischemiareperfusion injury (Xu et al, 2018), endometritis in cattle and peritonitis (Kelly et al, 2019). Although some studies are limited to in vitro applications, MCC950 is still considered to be a promising treatment, as it selectively blocks the interaction between NEK7 and NLRP3 (Wu et al, 2019).…”
Section: Inhibitors and Their Application To Diseasesmentioning
confidence: 99%
See 1 more Smart Citation
“…Third, how the neuronal autophagy affects neuronal function after hemorrhage and the related mechanism associated with NLRP3 should be more deeply evaluated. Recent studies and our present study have demonstrated the effectiveness of inhibiting NLRP3 expression by using MCC950 [54,55]. However, the time window and stability of MCC950 are very limited.…”
Section: Nucleotide-binding Oligomerization Domain-like Receptor Contmentioning
confidence: 62%